



Contents lists available at ScienceDirect

Journal of Industrial and Engineering Chemistry

journal homepage: www.elsevier.com/locate/jiec



Review

Senotherapy for attenuation of cellular senescence in aging and organ implantation

Dong Hoon Kang^a, Yeon Soo Park^a, Dong Yun Lee^{a,b,*}

^a Department of Bioengineering, College of Engineering, BK21 PLUS Future Biopharmaceutical Human Resources Training and Research Team, Hanyang University, Seoul 04763, Republic of Korea

^b Institute of Nano Science & Technology (INST), Hanyang University, Seoul 04763, Republic of Korea

ARTICLE INFO

Article history:

Received 20 June 2017
Received in revised form 28 August 2017
Accepted 29 August 2017
Available online xxx

Keywords:

Cellular senescence
Transplantation
Senolytic agent
Aging
Senescence-associated secretory phenotype

ABSTRACT

Cellular senescence in transplant is induced by aging and therapy-induced stress, which is caused by generation of senescent cells in transplant during engraftment. These senescent cells induce transplant failure due to secretion of senescence-associated secretory phenotype (SASP). So, elimination of senescent cells in transplant is important for successful comes. Recently, numerous studies have focused on the development of various senolytic agents such as dasatinib, quercetin, and navitoclax according to cellular type of transplant. Therefore, this study reviews the influence of cellular senescence in transplantation and capacity of senolytic agents as a new therapeutic strategy for successful outcomes of transplant.

© 2017 The Korean Society of Industrial and Engineering Chemistry. Published by Elsevier B.V. All rights reserved.

Contents

Introduction	00
Cellular senescence	00
Cellular senescence in transplantation	00
Kidney transplant as organ transplantation	00
Pancreatic islet transplant as cell-cluster transplantation	00
Stem cell transplant as single cell transplantation	00
Senolytic agent to remove the senescent cells	00
Dasatinib	00
Quercetin	00
Navitoclax	00
Pharmacokinetic parameters of senolytic agents	00
Limitations and utilization of senolytic agents	00
Conclusion	00
Conflict of interest	00
Acknowledgements	00
References	00

Introduction

Primary cells undergo a finite number of divisions before experiencing irreversible cell cycle arrest. However, when cells are exposed to oncogenic insults, the cell cycle is arrested by cellular senescence, demonstrating an anti-cancer effect to inhibit cancer cell division [1,2]. On the other hand, it is known that cellular

* Corresponding author at: Department of Bioengineering, College of Engineering, Hanyang University, 22 Wangsimni-ro, Seongdong-gu, Seoul 04763, Republic of Korea. Fax: +82 2 2220 4740.

E-mail address: dongyunlee@hanyang.ac.kr (D.Y. Lee).

<http://dx.doi.org/10.1016/j.jiec.2017.08.053>

1226-086X/© 2017 The Korean Society of Industrial and Engineering Chemistry. Published by Elsevier B.V. All rights reserved.

senescence cause general tissue dysfunction and aging [3–5], which is important in organ/cell transplantation. In practice, older donors are an unavoidable choice due to organ or cell shortage because the age can affect long-term survival of the transplant by increasing acute organ injury and reducing tissue regenerative capacity [6]. In addition, the transplants experience several stresses, including proteotoxic stress, oxidative stress, and DNA damage, which can also induce cellular senescence in the transplant. When senescent cells are occurred in the aged organ or transplanted cells, they secrete the senescence-associated secretory phenotype (SASP) molecules such as proinflammatory cytokines and growth factors, thereby affecting regenerative capacity, chronic inflammation and over-activity of metabolism. A recent study of senescence indicated that clearance of senescent

cells could delay aging-associated disorders [7]. In this review literature, therefore, we focus on the influence of cellular senescence in transplantation and a therapeutic opportunity to increase graft survival by using senolytic agent in a process called ‘senotherapy’.

Cellular senescence

The cellular senescence process consists of two pathways, i.e., the DNA-damaged response (DDR) pathway and the DDR-independent pathway (Fig. 1). The DDR pathway initiates exposure of uncapped free double-stranded chromosome ends by telomere erosion. In sequence, ataxia telangiectasia mutated (ATM), a damage sensor, induces the stabilization of tumor




Fig. 1. Effector pathways of senescence. A variety of stresses can activate the cellular senescence process. These stressors generate various cellular signaling cascades. DDR dependent or DDR-independent pathways activate p16^{ink4a} or p53/p21 pathways, accelerating senescence process. Senescent cells can loss of regenerative capacity and induce inflammation through secretion of SASP, such as proinflammatory cytokine, proteinases, and growth factor.

Download English Version:

<https://daneshyari.com/en/article/6666737>

Download Persian Version:

<https://daneshyari.com/article/6666737>

[Daneshyari.com](https://daneshyari.com)